Medical Xpress
Scientists crack an 'undruggable' childhood cancer protein, opening a path to treatments for neuroblastoma
Researchers at Linköping University have identified how to block two key cancer-related proteins from working together, a breakthrough targeting what was previously considered an untreatable molecular mechanism. The finding offers a promising new avenue for developing drugs against neuroblastoma, an aggressive cancer that primarily strikes young children. The study, published in Nature Communications, marks a significant step forward in tackling one of pediatric oncology's most stubborn challenges.
Read article →Medical Xpress
Bowel cancer immunotherapy clinical trial follow-up shows zero relapses
Patients enrolled in the NEOPRISM-CRC trial who received pre-surgical immunotherapy for a specific bowel cancer subtype have shown zero relapses after nearly three years of follow-up — a striking result for a treatment replacing standard post-operative chemotherapy. The findings, led by researchers at UCL and UCLH, suggest that a short course of immunotherapy administered before surgery may be a more effective and less burdensome approach. If the results hold at scale, this could signal a significant shift in how this cancer type is managed clinically.
Read article →Medical Xpress
Protective 'switch' in most common blood cancer opens new doors for diagnosis and treatment
Researchers at the Josep Carreras Leukaemia Research Institute have identified a protein called HDAC7 that acts as a critical biological "off switch" in diffuse large B cell lymphoma, the most common form of blood cancer. When HDAC7 is absent in cancer cells, the disease becomes markedly more aggressive — a finding that reframes how scientists understand the protein's role in both healthy immune function and malignancy. The discovery opens potential new avenues for earlier diagnosis and more targeted treatment strategies in DLBCL.
Read article →Medical Xpress
Washington expands hepatitis C testing, cutting per-patient costs by more than 45%
Washington State has broadened its hepatitis C testing program, slashing per-patient costs by over 45% and improving access to a disease that remains the most common bloodborne illness in the country. Despite treatments that cure the infection in more than 95% of cases, hepatitis C continues to disproportionately affect low-income and marginalized populations. Expanding testing is a critical step toward closing that gap.
Read article →Medical Xpress
These blood markers can expose colorectal, lung and ovarian cancers before symptoms appear
Researchers at Uppsala University have identified blood-based biomarkers capable of detecting colorectal, lung, and ovarian cancers before symptoms emerge, with performance matching or surpassing existing diagnostic tests. The findings mark a significant step toward non-invasive early cancer screening that could realistically be integrated into clinical practice. Earlier detection of these cancers dramatically improves survival odds, making the development of reliable blood tests a potential game-changer in oncology.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →